- Home
- SLS vs GNFT Comparison
SLS vs GNFT Comparison
Compare SLS & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- GNFT
- Stock Information
- Founded
- SLS 2012
- GNFT 1999
- Country
- SLS United States
- GNFT France
- Employees
- SLS N/A
- GNFT N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLS Health Care
- GNFT Health Care
- Exchange
- SLS Nasdaq
- GNFT Nasdaq
- Market Cap
- SLS 165.6M
- GNFT 186.3M
- IPO Year
- SLS N/A
- GNFT 2019
- Fundamental
- Price
- SLS $1.66
- GNFT $3.80
- Analyst Decision
- SLS Strong Buy
- GNFT Strong Buy
- Analyst Count
- SLS 1
- GNFT 1
- Target Price
- SLS $7.00
- GNFT $13.00
- AVG Volume (30 Days)
- SLS 2.8M
- GNFT 3.0K
- Earning Date
- SLS 08-12-2025
- GNFT 09-18-2025
- Dividend Yield
- SLS N/A
- GNFT N/A
- EPS Growth
- SLS N/A
- GNFT N/A
- EPS
- SLS N/A
- GNFT 0.03
- Revenue
- SLS N/A
- GNFT $73,187,701.00
- Revenue This Year
- SLS N/A
- GNFT $5.15
- Revenue Next Year
- SLS N/A
- GNFT N/A
- P/E Ratio
- SLS N/A
- GNFT $124.11
- Revenue Growth
- SLS N/A
- GNFT 105.01
- 52 Week Low
- SLS $0.77
- GNFT $2.55
- 52 Week High
- SLS $2.27
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- SLS 41.18
- GNFT 45.09
- Support Level
- SLS $1.75
- GNFT $3.94
- Resistance Level
- SLS $1.96
- GNFT $4.19
- Average True Range (ATR)
- SLS 0.12
- GNFT 0.11
- MACD
- SLS -0.04
- GNFT 0.01
- Stochastic Oscillator
- SLS 18.56
- GNFT 24.06
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.